Dr. Elias on Androgen Receptor Inhibitors in HER2-Positive Breast Cancer

Anthony D. Elias, MD
Published: Tuesday, Aug 04, 2015



Anthony D. Elias, MD, professor, Division of Medical Oncology, University of Colorado School of Medicine, discusses using androgen receptor inhibitors as a potential treatment of patients with HER2-positive breast cancer.

Androgen receptors signal several pathways such as EGFR, mTOR and cell cycle, creating feedback interactions and loops between them, Elias explains. For example, androgen receptors upregulate and control HER2 and HER3 expression in both ER-positive and HER2-positive disease. There is also direct interaction with amphiregulin and triple-negative disease, he adds. Researchers believe that androgen receptors will promote growth and blockage of the pathway using various androgen receptor agents often used for the treatment of prostate cancer.

Studies examining androgen receptor therapies in HER2-positive breast cancer are ongoing, Elias says. More research in this area is expected to be developed with the hopes of discovering an emerging biomarker.

SELECTED
LANGUAGE


Anthony D. Elias, MD, professor, Division of Medical Oncology, University of Colorado School of Medicine, discusses using androgen receptor inhibitors as a potential treatment of patients with HER2-positive breast cancer.

Androgen receptors signal several pathways such as EGFR, mTOR and cell cycle, creating feedback interactions and loops between them, Elias explains. For example, androgen receptors upregulate and control HER2 and HER3 expression in both ER-positive and HER2-positive disease. There is also direct interaction with amphiregulin and triple-negative disease, he adds. Researchers believe that androgen receptors will promote growth and blockage of the pathway using various androgen receptor agents often used for the treatment of prostate cancer.

Studies examining androgen receptor therapies in HER2-positive breast cancer are ongoing, Elias says. More research in this area is expected to be developed with the hopes of discovering an emerging biomarker.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x